McCormack, SM;
Gafos, M;
Desai, M;
Cohen, MS;
(2014)
Biomedical prevention: state of the science.
Clin Infect Dis
, 59 Suppl 1
S41 - S46.
10.1093/cid/ciu297.
![[thumbnail of Clin_Infect_Dis.-2014-McCormack-S41-6.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
Clin_Infect_Dis.-2014-McCormack-S41-6.pdf Download (100kB) |
Abstract
Preexposure prophylaxis (PrEP) and treatment as prevention (TasP) involve the use of antiretroviral (ARV) drugs by human immunodeficiency virus (HIV)-negative and -positive individuals to reduce HIV acquisition and transmission, respectively. Clinical science has delivered a consistently high effect size for TasP and a range from 0%-73% reduction in incidence across placebo-controlled PrEP trials. However, the quality of evidence for PrEP compares favorably with evidence for postexposure prophylaxis (PEP). It is clear from treatment programs and PrEP trials that daily adherence presents challenges to a large proportion of the population. Although there are factors associated with inconsistent use (ie, younger age), they do not assist clinicians at the point of care. There are additional provider concerns about PrEP (covering cost of drug and delivery, undermining condom promotion, and facilitating resistant strains) that have delayed widespread acceptance. These issues need to be addressed in order to realize the full public health potential of antiretrovirals.
| Type: | Article |
|---|---|
| Title: | Biomedical prevention: state of the science. |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/cid/ciu297 |
| Publisher version: | http://dx.doi.org/10.1093/cid/ciu297 |
| Language: | English |
| Additional information: | © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | PrEP, TasP, postexposure prophylaxis, preexposure prophylaxis, treatment as prevention, Anti-HIV Agents, HIV Infections, Humans, Public Health |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1460781 |
Archive Staff Only
 |
View Item |
